Forchheim, Germany Clinical Trials

A listing of Forchheim, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 129 clinical trials
featured
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.

antihypertensive drugs
hypertensive medication
angiography
hypertension
renal angiogram
University Clinic Erlangen
 (8.7 away) Contact site
  • 897 views
  • 10 Sep, 2021
  • +82 other locations
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

The purpose of this study is to evaluate the objective response rate (complete response [CR]+ partial response [PR]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.

erdafitinib
adjuvant chemotherapy
measurable disease
renal function
dose regimen
Waldkrankenhaus St. Marien -Urologische Universit tsklinik-
 (8.7 away) Contact site
  • 40 views
  • 17 Sep, 2021
  • +157 other locations
Efficacy Safety and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. …

apremilast
Research site
 (8.7 away) Contact site
  • 279 views
  • 08 Aug, 2021
  • +268 other locations
Trial of Andexanet in ICH Patients Receiving an Oral FXa Inhibitor

Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet versus usual standard of care in patients with intracranial hemorrhage anticoagulated with a direct oral anticoagulant

Universit tsklinik Erlangen, Neurologische Klinik
 (8.7 away) Contact site
  • 19 views
  • 17 Jul, 2021
  • +180 other locations
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

This study will evaluate whether adult participants with moderate to severe plaque psoriasis who have been treated with secukinumab or ixekizumab for at least 6 months and are experiencing a suboptimal response may benefit from switching to risankizumab with regard to skin symptoms, quality of life symptoms and psoriasis symptoms. …

ixekizumab
secukinumab
Universitaetsklinikum Erlangen /ID# 214228
 (8.7 away) Contact site
  • 49 views
  • 03 Jul, 2021
  • +80 other locations
A Study to Determine the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Universitaetsklinikum Erlangen /ID# 214196
 (8.7 away) Contact site
  • 22 views
  • 06 Aug, 2021
  • +49 other locations
Re-evaluation of Optimal Re-synchronisation Therapy in Patients With Chronic Heart Failure

The objective of the study is to demonstrate that in patients with chronic heart failure who receive optimal medical treatment for this condition and have indication for Cardiac Resynchronisation Therapy, the implantation of a pacemaker (index group) is not inferior to defibrillator (control group) with respect to all-cause mortality.

cardiac resynchronization therapy
ejection fraction
cardiomyopathy
medical therapy
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 2 views
  • 25 Sep, 2021
  • +355 other locations
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Research Site
 (8.7 away) Contact site
  • 52 views
  • 22 Sep, 2021
  • +224 other locations
Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

The objective of this study is to investigate the effect of K-321 in patients with Fuchs endothelial corneal dystrophy (FECD) after descemetorhexis.

corneal dystrophy
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 2 views
  • 09 Aug, 2021
  • +35 other locations
Linerixibat Long-term Safety and Tolerability Study

This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 [NCT01899703], 201000 GLIMMER [NCT02966834] (group 1) or 212620 GLISTEN [NCT00210418]) (group 2). All …

cholangitis
cholestatic pruritus
GSK Investigational Site
 (8.7 away) Contact site
  • 5 views
  • 23 Aug, 2021
  • +24 other locations